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Markov Modeling of Breast Cancer 
 
Chunling Cong Chris P. Tsokos 
University of South Florida
 
 
Previous work with respect to the treatments and relapse time for breast cancer patients is extended by 
applying a Markov chain to model three different types of breast cancer patients: alive without ever 
having relapse, alive with relapse, and deceased. It is shown that combined treatment of tamoxifen and 
radiation is more effective than single treatment of tamoxifen in preventing the recurrence of breast 
cancer. However, if the patient has already relapsed from breast cancer, single treatment of tamoxifen 
would be more appropriate with respect to survival time after relapse. Transition probabilities between 
three stages during different time periods, 2-year, 4-year, 5-year, and 10-year, are also calculated to 
provide information on how likely one stage moves to another stage within a specific time period. 
 
Key words: Markov chain, breast cancer, relapse time, tamoxifen and radiation. 
 
 
Introduction 
The Markov (1906) chain model has been 
applied in various fields such as physics, 
queuing theory, internet application, economics, 
finance, and social sciences among others. As an 
effective and efficient way of describing a 
process in which an individual moves through a 
series of states (stages) in continuous time, 
homogeneous Markov models have also been 
extensively used in health sciences where the 
progression of certain diseases are of great 
importance to both doctors and patients. In the 
present study, the main objective is to 
investigate the progression of breast cancer in 
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patients in three different stages who were given 
different treatments. One group of patients 
received combined treatments of tamoxifen and 
radiation, and the other group received only 
tamoxifen. Figure 1 shows the three stages of 
interest in the study are: alive with no relapse, 
alive with relapse, and deceased. Even though 
breast cancer patients who have recurrence may 
be treated and recover from breast cancer to 
become active with no relapse, due to the fact 
that the data does not include any observations 
of that process, we consider the second state- 
alive with relapse as those patients who once 
had relapse and are still alive, regardless of 
whether they have recovered from breast cancer 
or not.  
 
 
 
 
 
 
 
 
 
 
 
Methodology 
Between December 1992 and June 2000, a total 
of 769 women were enrolled and randomized in 
the study. Among these, 386 received combined 
radiation and tamoxifen (RT+Tam), and the 
Figure 1: Three Stages of Breast Cancer 
Modeling 
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remaining 383 received tamoxifen (Tam) only. 
The last follow-up was conducted in the summer 
of 2002. As shown in Figure 2, only those 641 
patients enrolled at the Princess Margaret 
Hospital are included: 320 and 321 in RT+Tam 
and Tam treatment groups, respectively. 
 
Figure 2: Breast Cancer Data 
 
 
 
 
 
 
 
 
 
This data was used by Fyles, et al. and 
was later analyzed by Ibrahim, et al. Analysis 
was conducted on this data with respect to the 
treatment effect of the two different treatments 
using decision tree and modeled relapse time 
using AFT and Cox-PH model. Mixture models 
were also applied to compare the cure rate of the 
two groups. 
 
The Markov Chain Model 
The Markov chain is a model for a finite 
or infinite random process sequence 
1 2,...,{ , }.NXX X X=  Unlike the independent 
identical distribution (i.i.d) model that assumes 
the independency of a sequence of events iX ’s, 
the Markov model takes into account the 
dependencies among the iX ’s. 
Consider a random process 
1 1, 2{ } { ,...}t tX X X X≥= =  of random variables 
taking values in a discrete set space of stages
{1, 2,3,..., }S s= where tX  represents the state 
of the process of an individual at time t. The 
transitions possible among the three stages in 
this study, alive without relapse, alive with 
relapse, and deceased are shown in Figure 1 
indicated by arrows. Consider a realization of 
the history of the process up to and including 
time t, as 1 1 1 1{ , ,..., },t t t tX x X x X x− −= = =  
where 1 1, ,...,t tx x x−  is a sequence of stages at 
different times. A random process is called a 
Markov Chain if the conditional probabilities 
between the stages at different times satisfy the 
Markov property: the conditional probability of 
future one-step-event conditioned on the entire 
past of the process is just conditioned on the 
present stage of the process. In other words, the 
one-step future stage depends only on the 
present stage:  
 
1 1 1 1 1 1
1 1
( | , ,..., )
( | )
t tt t t t
t tt t
P X x X x X x X x
P X x X x
+ + − −
+ +
= = = =
= = =
  (1) 
 
for every sequence 1 1,..., ,t tx x x + of elements of 
S  and every 1t ≥ .  
The transition probability from stage i to 
stage j  at time t  and transition intensity are 
defined by 
1( ) ( | )ij t tp t p X j X i+= = = ,        (2) 
and 
0
( ( ) | ( ) )( ) limij h
P X t h j X t iq t
h→
+ = =
= ,  (3) 
 
where h  is the time interval. 
If the transition probabilities do not 
depend on time, ( )ijp t  can simply be written as
ijp , then the Markov chain is called time-
homogeneous. If not specified, the following 
analysis is based on time-homogeneous Markov 
chain. A transition probability matrix ( )P t  
consisting of all the transition probabilities 
between stages in a matrix form is given by: 
 
11 12 1
21 22 2
1 2
( ) ( ) ... ( )
( ) ( ) ... ( )
( ) ,
... ... ... ...
( ) ( ) ... ( )
s
s
s s ss
p t p t p t
p t p t p t
P t
p t p t p t
   
=     
   (4) 
 
where probabilities in each row add up to 1. 
Thus, it is 100% certain that for any individual 
at time t is in one of the stages and the sum of 
probabilities of being in each stage is 1. 
The transition probability matrix can be 
calculated by taking the matrix exponential of 
the scaled transition intensity matrix defined by  
 
( ) ( )P t Exp tQ= ,                    (5) 
641Total  
320 
RT+Tam 
321 
Tam 
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where 
 
11 12 1
21 22 2
1 2
...
...
... ... ... ...
...
s
s
s s ss
q q q
q q q
Q
q q q
   
=     
,             (6) 
 
and ijq denotes the transition intensity from 
stage i  to stage j . 
The exponential of a matrix A  is 
defined by  
 
2 3( ) 1 / 2! / 3! ...Exp A A A= + + + ,     (7) 
 
where each summand in the series is the matrix 
products. In this manner, once the intensity 
matrix is given, the transition probabilities can 
be calculated as shown above. 
Next, the intensity matrix and transition 
probabilities matrix can be obtained by 
maximizing the likelihood ( )L Q which is a 
function ofQ . Consider an individual consisting 
of a series of times 1 2( , ,..., )nt t t  and 
corresponding stages 1 2( , ,..., ).nx x x  More 
specifically, consider a pair of successive stages 
observed to be i and j  at time it  and jt . Three 
scenarios are proposed and considered here. 
 
Scenario 1 
If the information for the individual is 
obtained at arbitrary observation times (the exact 
time of the transition of stages is unknown) the 
contribution to the likelihood from this pair of 
states is: 
( )ij ij j iL p t t= − .                    (8) 
 
Scenario 2 
If the exact times of transitions between 
different stages are recorded and there is no 
transition between the observation times, the 
contribution to the likelihood from this pair of 
stages is: 
( ) .ij ij j i ijL p t t q= −                    (9) 
 
 
Scenario 3 
If the time of death is known or
j death= , but the stage on the previous instant 
before death is unknown as denoted by k  ( k
could be any possible stage between stage i and 
death), the contribution to the likelihood 
function from this pair of stages is: 
 
( ) .ij ik j i kj
k j
L p t t q
≠
= −              (10) 
 
Results 
The breast cancer patients were divided into two 
groups RT+Tam and Tam based on the different 
treatments they received. For those patients who 
received combined treatments, 26 patients 
experienced relapse, 13 patients died without 
recurrence of breast cancer during the entire 
period of the study, and 14 died after recurrence 
of breast cancer. For the patients in the Tam 
group, 51 patients experienced relapse, 10 died 
without reoccurrence of breast cancer, and 13 
died after recurrence of breast cancer. 
As can be observed from the transition 
intensity matrixes for both groups RT+Tam and 
Tam as shown in Tables 1 and 2, patients who 
received single treatment have a higher 
transition intensity form Stage 1 to Stage 2, thus, 
they are more likely to have breast cancer 
recurrence. Thus, the probability of that 
happening in the Tam group is higher than that 
of the RT+Tam group. For those patients who 
died without relapse, there is no significant 
difference between the two treatments as 
illustrated by the intensity form Stage 1 to Stage 
3. 
Combined treatment is also more 
effective than a single treatment with respect to 
the possibility of death without relapse as can be 
observed from the transition intensity from 
Stage 1 to Stage 3. However, for those who 
already experienced relapse of breast cancer, 
patients who received combined treatments are 
more likely to die than those who received a 
single treatment. Therefore, combined treatment 
should be chosen over single treatment to avoid 
recurrence, but for those patients who already 
had breast cancer relapse, it would be advisable 
to choose a single treatment to extend the time 
from recurrence to death. 
CONG & TSOKOS 
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Figures 3 and 4 illustrate the 
effectiveness of the two treatments with respect 
to the survival probabilities and also show the 
survival curves of the patients who had 
recurrence and who had no recurrence in each 
treatment group. 
From the above analysis, the proposed 
Markov chain model provides recommendations 
for which treatment to choose for breast cancer 
patients with respect to relapse and survival 
time. Moreover, it provides patients with very 
important information on the exact time or 
possibilities of recurrence and death. Estimated 
mean sojourn times in each transient stage for 
patients who received combined treatment are 
43.46 and 3.25 in Stage 1 and Stage 2, 
respectively. Estimated mean sojourn times for 
patients who received single treatment are 25.53 
and 11.72 in Stage 1 and Stage 2. This further 
confirms that patients with combined treatment 
will remain in Stage 1 longer than those with 
single treatment; however, for patients who had 
relapse of breast cancer, patients with single 
treatment will stay alive longer than those with 
combined treatment. 
Another goal of this study was to 
provide a transition probability matrix at 
different times so that given a specific time 
period, the probability that a patient in a given 
stage will transit to another stage could be 
conveyed. Tables 5a-8b give 2-year, 4-year, 5-
year and 10-year transition probability matrixes 
of patients in RT+Tam and Tam. 
 
Conclusion 
Through Markov chain modeling of the three 
stages of breast cancer patients , it has been 
shown that combined treatment of tamoxifen 
and radiation is more effective than single 
treatment of tamoxifen in preventing the 
recurrence of breast cancer. However, for 
patients who had a relapse of breast cancer, 
single treatment of tamoxifen proves to be more 
effective than combined treatment with respect 
to the survival probability. This finding could 
give significant guidance to doctors with respect 
to which breast cancer treatment should be given 
to breast cancer patients in different stages. 
Transition probabilities between different stages 
during 2 years, 4 years, 5 years and 10 years are 
also calculated for predicting purposes. Those 
transition probabilities could help provide a 
clearer view of how one stage transits to another 
stage within a given time period. 
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Table 1: Transition Intensity Matrix of RT+Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 -0.02301 0.01957 0.0034 
Stage 2 0 -0.3074 0.3074 
Stage 3 0 0 0 
 
Table 2: Transition Intensity Matrix of Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 -0.03917 0.03528 0.003889 
Stage 2 0 -0.08533 0.08533 
Stage 3 0 0 0 
Figure 3: Survival Curves of Patients in RT+Tam 
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Table 5a: 2-year transition matrix for RT+Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.9550 0.0285 0.0165 
Stage 2 0 0.5408 0.4592 
Stage 3 0 0 0 
 
Table 6a: 4-year transition matrix for RT+Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.9121 0.0426 0.0453 
Stage 2 0 0.2925 0.7075 
Stage 3 0 0 0 
 
Table 7a: 5-year transition matrix for RT+Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.8913 0.0466 0.0621 
Stage 2 0 0.2151 0.7849 
Stage 3 0 0 0 
 
Table 8a: 10-year transition matrix for RT+Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.7945 0.0515 0.1540 
Stage 2 0 0.0463 0.9537 
Stage 3 0 0 0 
 
Table 5b: 2-year transition matrix for Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.9247 0.0623 0.0130 
Stage 2 0 0.8431 0.1569 
Stage 3 0 0 0 
 
Table 6b: 4-year transition matrix for Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.8550 0.1102 0.0348 
Stage 2 0 0.7108 0.2892 
Stage 3 0 0 0 
 
Table 7b: 5-year transition matrix for Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.8221 0.1295 0.0484 
Stage 2 0 0.6527 0.3473 
Stage 3 0 0 0 
 
Table 8b: 10-year transition matrix for Tam 
 Stage 1 Stage 2 Stage 3 
Stage 1 0.6759 0.1910 0.1331 
Stage 2 0 0.4260 0.5740 
Stage 3 0 0 0 
 
Figure 4: Survival Curves of Patients in Tam 
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